Sichuan Qiyu Pharmaceutical Technology

Sichuan Qiyu Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of targeted protein degraders (TPDs) for oncology and other complex diseases. Based in Chengdu, China, the company utilizes its proprietary PROTAC and molecular glue platforms to design small molecules that harness the body's natural protein disposal system to eliminate disease-causing proteins. Its lead program, QY-101, is an androgen receptor degrader currently in Phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer. The company's pipeline also includes candidates targeting the estrogen receptor for breast cancer and Bruton's tyrosine kinase for hematological malignancies. Qiyu is led by a team of scientists with deep expertise in medicinal chemistry and has secured significant venture capital funding from investors like HighLight Capital and IDG Capital. By focusing on previously undruggable targets, Qiyu aims to provide transformative therapeutic options for patients with limited treatment alternatives.